

To evaluate the efficacy, safety and tolerability of Hilterapia® (High Intensity Laser Therapy) in the chronic articular inflammatory processes in haemophilic adult patients

Submission date 27/07/2011	Recruitment status No longer recruiting	☐ Prospectively registered
		☐ Protocol
Registration date 13/09/2011	Overall study status Completed	☐ Statistical analysis plan
		☐ Results
Last Edited 14/02/2017	Condition category Haematological Disorders	☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol

Background and study aims

Haemophilia is an inherited condition that affects the blood's ability to clot, which can lead to bleeding into the joints and inflammation. The aim of this study is to assess the effectiveness, safety and tolerability of high-intensity laser therapy (HILT) for the treatment of joint inflammation in haemophiliac patients.

Who can participate?

Patients aged 18 and over with haemophilia A

What does the study involve?

All participants receive nine applications of HILT (three applications per week over 3 weeks). Pain is assessed before, during and after treatment.

What are the possible benefits and risks of participating?

It is not known for certain whether the participant will benefit, but as HILT is already used successfully in other diseases, it could help. The risks of HILT are the following reactions related to the application area: warm with possibly burning sensation, local sensitivity alteration, tingling, numbness, rush and oedema (build-up of fluid).

Where is the study run from?

IRCCS Ospedale Maggiore di Milano (Italy)

When is the study starting and how long is it expected to run for?

May 2011 to December 2011

Who is funding the study?

Baxter (Italy)

Who is the main contact?

Dr Michele Schino

Contact information

Type(s)

Scientific

Contact name

Dr Elena Santagostino

Contact details

Centro Emofilia e Trombosi
Angelo Bianchi Bonomi
Dipartimento di Medicina Interna
IRCCS Ospedale Maggiore di Milano
Via Pace, 9
Milan
Italy
20122

Additional identifiers

Protocol serial number

HILT-haemophilia-2011

Study information

Scientific Title

To evaluate the efficacy, safety and tolerability of Hilterapia® (High Intensity Laser Therapy) in the chronic articular inflammatory processes in haemophilic adult patients: an interventional pilot multicentre study

Study objectives

Previous experimental studies (Fortune, 2002) indicate how the laser can be antagonistic to degenerative phenomenon, experimentally induced, to stimulate neo-chondrogenesis with formation of simil-jalina cartilage and to induce synovial hyperplasia; these effects appear to be particularly related to variations in light intensity (power intensity: W/cm²) rather than when supplied in doses (Joule J/cm²).

Ethics approval required

Old ethics approval format

Ethics approval(s)

Ethics Comittee of the Foundation of the Institute of Medical Research of a Public Nature and the City Council of Milan [Comitato di Etica della Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano], 22/03/2011

Primary study design

Interventional

Study design

Interventional pilot multicenter study

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Haemophilia

Interventions

Therapy with the equipment ASA-SH1 involves 9 applications (3 applications per week x 3 weeks) of Hilterapia® with the following operating parameters:

1. Fluence: 360 to 760 mJ/cm²
2. Frequency: 10 - 35 Hz
3. Total energy: 500 to 1,500 J
4. Time of application: 6 - 11 minutes

Subjects will be requested to attend 10 clinical visits in total: T1 (screening/first treatment), T2-T9 (HILT application visits) and T10 (final visit).

Intervention Type

Other

Phase

Not Applicable

Primary outcome(s)

1. Pain will be measured using the Visual Analogue Scale (VAS) score (0 = no pain, 10 = unbearable pain) at baseline (T1), T4, T7 and T10 visits
2. Nieschls Score and the articular state will be measured using Hemophilia Joint Health Score 2.0

Key secondary outcome(s)

No secondary outcome measures

Completion date

31/12/2011

Eligibility

Key inclusion criteria

1. Adult subjects with haemophilia A of any severity with or not suppressant
2. Age more than or equal to 18 years
3. Subjects who have been previously diagnosed with a chronic articular inflammatory process or hematoma
4. Subjects who have signed an informed written consent

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 Years

Sex

All

Key exclusion criteria

Subjects with under way bleeding

Date of first enrolment

15/05/2011

Date of final enrolment

31/12/2011

Locations**Countries of recruitment**

Italy

Study participating centre

IRCCS Ospedale Maggiore di Milano

Milan

Italy

20122

Sponsor information**Organisation**

Baxter (Italy)

ROR

<https://ror.org/02kf9ya90>

Funder(s)**Funder type**

Industry

Funder Name

Baxter (Italy)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration